A new study has found that most people who stopped using semaglutide, the active ingredient in popular weight-loss medications such as Ozempic, regained around two-thirds of the weight they had lost and saw their health indicators worsen, including increases in blood pressure, cholesterol and the risk of heart disease

Wegovy and Ozempic are known as GLP-1 receptor agonists and cause weight loss by mimicking the actions of GLP-1, a hormone in the brain that regulates appetite and feelings of fullness.

According to the study, around 12 percent of adults in the US are reported to have used at least one GLP-1 receptor agonist, while 6 percent said they are currently using one.

Around 85 percent of people who had started using medications such as Ozempic stopped taking them within two years, and 71 percent stopped within the first year.

Mounjaro and its use

Although it appears to be the most talked-about, Ozempic is not the only widely used medication for weight loss. Mounjaro is another one.

Mounjaro and Ozempic are different drugs, although they work in a similar way. Mounjaro is a GLP-1 and GIP receptor agonist. Ozempic acts only on GLP-1. Both are approved to lower blood sugar in people with type 2 diabetes, in combination with a healthy diet and exercise.

While Mounjaro and Ozempic are indeed diabetes medications, they can also help you lose weight.

Why users stop taking them

For two reasons: either because they had reached their desired weight or because the drugs are very expensive, around 2,000 dollars.

Since it became available, semaglutide has shown success not only in treating diabetes and obesity, but new research also shows that it plays a positive role in lowering blood pressure and reducing the risk of heart attacks or strokes.

But using it for weight loss may not be just as beneficial.

A study conducted by researchers at Northwestern University reported that, while it is unclear how stopping GLP-1 receptor agonists affects long-term heart health, the findings suggest that it may increase cardiovascular risk.

However, given the high rate of discontinuation of such medications and the negative side effects that follow, the researchers said it is essential to study whether starting these drugs offers any long-term benefits and reduces people's health risks, or whether the drawbacks of stopping the medications outweigh the benefits.

While the researchers behind the latest study did not definitively say that patients would have to use these drugs for life to keep their conditions under control, their findings show that people using GLP-1 receptor agonists for weight management and improved cardiometabolic health may also need long-term use.

What happens when you stop Ozempic?

Stopping Ozempic was also linked to a worsening in the levels of several risk factors for cardiovascular and metabolic health, which play a role in heart health and diabetes.

Previous research has found that, after 68 weeks of injections, the average patient lost more than 15 percent of their body weight.

However, within 12 months of completing treatment, around 300 patients regained around two-thirds of the weight they had lost.

The researchers added that doctors and patients should also discuss what could happen if the therapy is stopped.

Dr. Domenica Rubino, director of the Center for Weight Management and Research in Washington, told the BBC: “Obesity is not like an infection where you take antibiotics and everything is cured. Unlike hypertension, diabetes and many other chronic diseases we treat, where you have to use chronic medications, such as statins for heart health, those who stop taking the drugs may experience unwanted consequences. There have been numerous reports of dangerous side effects in those actively using semaglutide, such as severe nausea and vomiting, suicidal thoughts and stomach paralysis,” she said.

Ozempic’s entry into the pharmaceutical market was initially approved by the FDA to manage diabetes, and its “twin” drug Wegovy, now approved for weight loss, marked a major shift in how doctors treat obesity.

These medications have been shown to help people lose around five to 20 percent of their body weight. The widespread use of the medications has already affected national obesity rates, which have fallen by nearly five percent in one year.

Approximately five million Americans were prescribed semaglutide in 2023, and almost four in 10 were using it specifically for weight loss, rather than diabetes management, Anabel reports.

The researchers emphasized: “The use of GLP-1 receptor agonists is likely to continue to grow rapidly in the US as coverage indications expand. But the alarming rates of discontinuation of GLP-1 receptor agonists should attract the attention of doctors, policymakers and public health experts.” /Telegrafi/